6 June 2023 - NICE has published evidence-based recommendations for daratumumab (Darzalex) for use in combination with bortezomib and dexamethasone for adults with previously treated multiple myeloma.

Daratumumab, when used in combination with bortezomib and dexamethasone, is recommended as an option for the treatment of adults with multiple myeloma only if they have had just one previous line of treatment and it included lenalidomide or lenalidomide is unsuitable as a second-line treatment.

Daratumumab is recommended only if Janssen provides it according to the commercial arrangement.

Read NICE technology appraisal guidance